A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis

NCT07754786 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab Injection
DRUG: IBI3027

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.